Cantor Fitzgerald lowered its price target for Eli Lilly and Company following data related to its obesity medicines.
1 report, 1 independent
Updated Aug 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald lowered its price target for Eli Lilly and Company following data related to its obesity medicines.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Cantor Fitzgerald
American financial services company
Related events
- Barclays dropped its target price and set an underweight rating, while Cantor Fitzgerald also issued an underweight rating for Polestar.
- Eli Lilly's tirzepatide proved more effective than Novo Nordisk's semaglutide in the obesity drug market.
- Multiple financial firms, including Raymond James, Wells Fargo, UBS, Cantor Fitzgerald, and KeyCorp, issued rating updates and target price changes on November 2, 2026.
- Benzinga reported analyst research notes and Cantor Fitzgerald decreased its price objective for EMCOR Group, Inc.
- Cantor Fitzgerald restated an overweight rating and Royal Bank of Canada reduced its price objective for United Therapeutics.
Coverage
Newest first; wire copies grouped- Insider MonkeyCantor Fitzgerald Slashes PT on Eli Lilly and Company (LLY) to $825 From $975 Eli Lilly and Company (NYSE:LLY) is one of the best stocks to invest in for beginners. On August 13, Cantor Fitzgerald an